Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Dec 1:7:122-124.
doi: 10.1016/j.jdcr.2020.11.016. eCollection 2021 Jan.

Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy

Katelyn Singh  1 , Alice Wang  1 , Peter Heald  1 , Jennifer M McNiff  1 , Kathleen Suozzi  1 , Brett King  1 , Jonathan Leventhal  1 , William Damsky  1
Affiliations
Case Reports

Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy

Katelyn Singh et al. JAAD Case Rep. .
No abstract available

Keywords: JAK inhibitor; JAK, Janus kinase; JAK-STAT; Janus kinase; PDL, pulsed dye laser; angiolupoid sarcoidosis; sarcoidosis; tofacitinib.

PubMed Disclaimer

Conflict of interest statement

Dr King is an investigator for Concert Pharmaceuticals Inc, Eli Lilly and Company, and Pfizer Inc; is a consultant to and/or investigator for and/or has served on advisory boards for Aclaris Therapeutics, Arena Pharmaceuticals, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences, Eli Lilly and Company, Pfizer Inc, and Viela Bio; and is on the speaker's bureau for Regeneron and Sanofi Genzyme. Dr Damsky has research funding from 10.13039/100004319Pfizer, is a consultant for Eli Lilly and Twi Biotechnology, and receives licensing fees from EMD/Sigma/Millipore in unrelated work. Authors Singh and Wang and Drs Heald, McNiff, Suozzi, and Leventhal have no conflicts of interest to declare.

Figures

Fig 1
Fig 1
Histologic and clinical features of sarcoidosis and response to tofacitinib ointment 2% and PDL. A, A biopsy from the upper portion of the left arm showed well-formed granulomas composed of epithelioid histiocytes and a sparse lymphocytic infiltrate. Stains for acid-fast bacilli and fungal organisms were negative. Polarization was negative. B, Clinical image at baseline (while the patient was taking methotrexate 15 mg weekly). C, Clinical image after 5 months of tofacitinib ointment 2% and before the second session of PDL. D, Clinical image after 1 year of tofacitinib 2% ointment treatment and 3 sessions of PDL. PDL, Pulsed dye laser.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Noe M.H., Rosenbach M. Cutaneous sarcoidosis. Curr Opin Pulm Med. 2017;23(5):482–486. - PubMed
    1. Wu M.C., Lee J.Y. Cutaneous sarcoidosis in southern Taiwan: clinicopathologic study of a series with high proportions of lesions confined to the face and angiolupoid variant. J Eur Acad Dermatol Venereol. 2013;27(4):499–505. - PubMed
    1. Wanat K.A., Rosenbach M. A practical approach to cutaneous sarcoidosis. Am J Clin Dermatol. 2014;15(4):283–297. - PubMed
    1. Broos C.E., Hendriks R.W., Kool M. T-cell immunology in sarcoidosis: disruption of a delicate balance between helper and regulatory T-cells. Curr Opin Pulm Med. 2016;22(5):476–483. - PubMed
    1. Damsky W., Thakral D., McGeary M.K., Leventhal J., Galan A., King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2020;82(3):612–621. - PMC - PubMed

Publication types

LinkOut - more resources